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BACKGROUND/PURPOSE: Ventilator-associated pneumonia (VAP) due to multidrug-resistant 
(MDR) Acinetobacter baumannii in critically ill patients presents an emerging challenge to clinicians. 
Administration of aerosolized colistin as an adjunctive therapy is one therapeutic option mentioned in 
limited evidence-based studies. This study aimed to evaluate the effectiveness of adjunctive aerosolized 
colistin treatment for VAP due to MDR pathogens.
METHODS: We retrospectively reviewed the medical records of patients who had received 
aerosolized colistin for treatment of VAP due to MDR A. baumannii in our hospital from August to 
December 2008.
RESULTS: Forty-five patients were enrolled in our study. The mean age was 71 ± 15 years. The mean 
Acute Physiological and Chronic Health Evaluation II (APACHE II) scores on the day of intensive care 
unit admission and on the first day of aerosolized colistin administration were 22.5 ± 6.7 and 18.9 ± 5.7, 
respectively. The mean duration of intensive care unit stay was 34 ± 16 days. The mean daily dosage 
of aerosolized colistin was 4.29 ± 0.82 million IU, and the mean duration of administration was 10.29 
days. Seventeen patients (37.8%) had a favorable microbiological outcome and 26 (57.8%) showed a 
clinical response. Mortality due to all causes was 42.2%. No adverse effects related to inhaled colistin 
were recorded.
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Introduction
Nosocomial pneumonia due to multidrug-resistant (MDR) 
Gram-negative bacteria such as Acinetobacter baumannii and 
Pseudomonas aeruginosa has become the most serious com-
plication for patients in intensive care units (ICUs). In the 
past decade, the virulence of these MDR pathogens is es-
pecially worrisome owing to limited therapeutic options.
Colistin (colistimethate sodium) is an antibiotic of the 
polymyxin family first used in 1960. Due to its nephro-
toxicity and neurotoxicity, it has not been the drug of 
choice since 1980. However, intravenous colistin has made 
a recent comeback for the treatment of MDR Gram-
negative bacterial pneumonia.1,2
The use of aerosolized colistin had been limited to 
patients with cystic fibrosis (CF).3 Currently, there are only 
a few reports indicating that aerosolized colistin may be 
a beneficial additional therapeutic intervention in the 
management of MDR bacterial pneumonia.4–7 Ventilator-
associated pneumonia (VAP) due to colistin susceptible-
only A. baumannii is one of the most severe complications 
in critically ill patients in our hospital. Owing to the pos-
sible toxicity of intravenous colistin, aerosolized colistin 
was considered to be an alternative treatment for VAP.
This study is a retrospective analysis of the efficacy of 
aerosolized colistin in a group of critically ill ICU patients 
suffering from MDR A. baumannii pneumonia. Additional 
risk factors and mortality were evaluated simultaneously.
Methods
Study design
Patients who received aerosolized colistimethate sodium 
(Colimycin, TTY Biopharm, Taipei, Taiwan) for more than 
72 hours for the treatment of MDR A. baumannii infection 
from August 1 to December 31, 2008 at Mackey Memorial 
Hospital (a 2,100-bed tertiary care centre in Taiwan, with 
72 beds in the medical and surgical ICU) were identified 
from the pharmacy electronic database and their medical 
records were carefully reviewed. Only patients under me-
chanical ventilation in the ICU were enrolled. Two million 
IU colistin was diluted in 4 mL sterile normal saline and 
then delivered to the patients via the same route through 
which they inhaled β2-agonists.
Data collection and entry
Data for several variables, including demographics, co-
morbidities and Acute physiological and Chronic Health 
Evaluation II (APACHE II) scores on ICU admission and 
on the first day of colistin treatment, the responsible patho-
gens and the results of laboratory tests were collected from 
medical records. All available data regarding renal func-
tion (serum creatinine and urea levels), liver function tests 
(serum alanine aminotransferase and aspartate aminotrans-
ferase levels) and white blood cell counts, platelet counts, 
and C-reactive protein levels during the course of aero-
solized colistin treatment (before and after) were recorded.
Microbiological testing
Antimicrobial susceptibility testing was performed using 
both the disk diffusion method and automated broth 
microdilution method (Vitek II, bioMerieux, Durham, NC, 
USA). The breakpoints were those defined by the Clinical 
and Laboratory Standards Institute.8 Intermediate sen-
sitivity of the isolated pathogens to the antimicrobial 
agents was considered to be resistance. MDR was defined 
as resistance to all anti-pseudomonal agents (i.e. anti-
pseudomonal penicillins, cephalosporins, carbapenems, 
monobactams, quinolones, and aminoglycosides).4 An iso-
late was defined as colistin-only susceptible when it was 
resistant to all anti-pseudomonas agents except colistin.
Definitions of pneumonia
Pneumonia was considered to be VAP when it occurred 
48 hours after the initiation of mechanical ventilation. 
Diagnosis of VAP was based on radiological (new or 
CONCLUSION: Aerosolized colistin may be considered as an adjunct to intravenous treatments in
patients with VAP due to colistin-susceptible MDR A. baumannii in critically ill patients.
KEYWORDS:  Acinetobacter baumannii, colistin, drug resistance, inhaled, nosocomial pneumonia, 
multiple, polymyxin
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progressive infiltrate), clinical (body temperature > 38°C 
or < 36°C) and laboratory findings (abnormal white 
blood cell count, C-reactive protein and gas exchange). 
The diagnosis of VAP due to MDR A. baumannii should be 
microbiologically confirmed by positive cultures of MDR 
A. baumannii from either bronchial secretions or broncho-
alveolar lavage samples of each patient, as in our study.
Definition of outcome
Clinical outcomes were classified as: (1) cured (resolution 
of presenting symptoms and signs of infection by the end 
of treatment); (2) improved (partial resolution of presenting 
symptoms and signs or infection); (3) failed (persistence 
or worsening of presenting symptoms and/or signs of in-
fection during colistin administration); or indeterminate 
(clinical assessment was not possible).
Microbiologic outcomes were assessed on the basis of 
the results of bronchial secretion cultures. The results were 
classified as: (1) eradication (no growth of the responsible 
pathogen); (2) persistence (persistent growth of the re-
sponsible pathogen); or (3) indeterminate (when micro-
biological assessment was not possible). Assessment of 
effectiveness was made at the end of colistin treatment.
Statistical analysis
Continuous variables were compared using the independent 
t test. Categorical variables were compared using the χ2 test 
or Fisher exact test. A p value of less than 0.05 was consid-
ered significant, and two-tailed test was adopted for all 
probabilities. All significant variables of univariate analysis 
were put into Logistic Regression analysis to calculate odds 
ratio so as to interpret the impact of independent variables 
on dependent variables. All statistical analysis was per-
formed with SPSS version 10.0 (SPSS Inc., Chicago, IL, USA).
Results
From August 1 to December 31, 2008, a total of 102 patients 
received aerosolized colistin for infections with MDR micro-
organisms. Of these, 32 had received less than 72 hours 
of aerosolized colistin and were excluded from all analy-
ses. Medical records were not available for 15 patients. In 
addition, four patients were still under treatment in the 
hospital during data collection. There were two patients 
with VAP due to Klebsiella pneumonia-ESBL (extended 
spectrum β-lactamase) and four patients with VAP due to 
A. baumannii (2 isolates were susceptible to meropenem 
and colistin, 1 was susceptible to imipenem–cilastatin and 
colistin, and 1 was susceptible to gentamicin and colistin). 
As a result, only 45 patients qualified for our study.
Demographic and clinical characteristics
Table 1 shows the demographic and clinical features of 
the patients, the responsible pathogens and the outcomes 
of the patients. The age of these 45 patients ranged from 
31 to 92 years (mean = 71 ± 15 years) and the majority were 
male (71.1%). Comorbidities were noted in all patients 
(most patients had more than one comorbidity). The mean 
APACHE II scores on the day of ICU admission and on 
the first day of aerosolized colistin administration were 
22.5 ± 6.7 and 18.9 ± 5.7, respectively. The mean length of 
ICU stay was 34 ± 16 days.
The pathogen responsible for VAP was MDR 
A. baumannii. All patients had received other antimicro-
bial regimens before aerosolized colistin. In addition, they 
all received concomitant intravenous treatment (6 patients 
with colistin and others with mainly carbapenems). All 
the isolated pathogens were susceptible to colistin only 
(in vitro susceptibility testing for tigecycline was unavaila-
ble in our hospital in 2008). The mean daily dosage of 
aerosolized colistin was 4.29 ± 0.82 × 106 IU, ranging from 
2 to 6 million IU (divided into 2 or 3 doses), and the mean 
duration of administration was 10.29 days.
The outcomes of treatment were as follows: 17 patients 
(37.8%) had a favorable microbiological outcome (eradica-
tion); eight (17.8%) had persistent infection; 26 (57.8%) 
had a favorable clinical outcome (clinically cured or im-
proved); and aerosolized colistin therapy failed in 14 
(31.1%). Death due to all causes was noted in 19/45 pa-
tients (a crude mortality rate of 42.2%). No adverse effects 
relating to inhaled colistin were recorded.
Laboratory and bacteriological characteristics
In terms of hematological and biochemical laboratory ex-
aminations, the abnormal data for patients before and 
after receiving aerosolized colistin therapy are shown in 
Table 2. In addition, we also recorded the bacteriological 
characteristics after receiving aerosolized colistin therapy. 
Twenty-seven patients (60.0%) had positive findings in their 
bronchial secretions or bronchoalveolar lavage. Only a 
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few specimens revealed more than one pathogen. The ma-
jority of the pathogens were Chryseobacterium meningosepti-
cum (9/27 patients) followed by colistin-only susceptible 
A. baumannii (8/27 patients); suggesting persistence of the 
responsible pathogen. However, as 18 patients (40.0%) 
had no subsequent culture data, their microbiological 
outcomes were inconclusive.
Mortality factors
Significant influential factors related to death were found 
in the univariate analysis (Table 3).These included comor-
bid pulmonary disease, APACHE II scores on first day of 
aerosolized colistin administration, length of hospital stay, 
platelet counts, blood urea nitrogen and serum creatinine 
levels and positive cultures from bronchial secretions or 
bronchoalveolar lavage.
Logistic regression analysis also showed that the mor-
tality odds ratio (OR) for creatinine (after receiving aero-
solized colistin therapy) was higher (OR = 7.558); however, 
it was not significant (p = 0.115).
Discussion
In recent years, strains of Acinetobacter spp. and P. aeruginosa 
have not been susceptible to the majority of antimicrobial 
Table 1. Demographical and clinical characteristic and out-
comes in patients receiving aerosolized colistin therapy for 
ventilator-associated pneumonia due to multidrug-resistant 
Acinetobacter baumannii (n = 45)a
Variable
Patient characteristics
 Age (yr) 71 ± 15 (31–92)
 Sex
  Male 32 (71.1)
  Female  13 (28.9) 
Comorbidity
 Hypertension 18 (40.0)
 Neurology disease 12 (26.7)
 Renal disease 16 (35.6)
 Cardiovascular disease 14 (31.1)
 Pulmonary disease 12 (26.7)
 Diabetes mellitus 10 (22.2)
 Neoplastic disease 7 (15.6)
 Operation 6 (13.3)
 Hepatic disease 3 (6.7)
APACHE II on ICU admission  22.5 ± 6.7 (6–35)
APACHE II on 1st day of aerosolized 18.9 ± 5.7 (8–30)
 colistin administration
Length of hospital stay (d) 65 ± 34 (14–165)
Length of ICU stay (d) 34 ± 16 (9–94)
Microbiology outcome
 Eradication 17 (37.8)
 Persistence of colistin susceptible-only
 Acinetobacter baumannii 8 (17.8)
 Indeterminate 20 (44.4)
Clinical outcome
 Cure or improvement 26 (57.8)
 Failure 14 (31.1)
 Indeterminate 5 (11.1)
Discharge from hospital 26 (57.8)
Death 19 (42.2)
aData presented as n (%) or mean ± standard deviation (range). 
APACHE II = Acute physiological and Chronic Health Evaluation; 
ICU = intensive care unit.
Table 2. Laboratory data for patients who received aero-
solized colistin therapy for ventilator-associated pneumonia 
due to multidrug-resistant Acinetobacter baumanniia
Variable Before therapy After therapy
Hematologic exams
 Leucopenia (< 4 × 109/L) 2/45 (4.4) 0/45 (0.0)
 Leukocytosis  36/45 (80.0) 28/45 (62.2)
  (> 10 × 109/L )
 Segment WBC (> 75%) 35/45 (77.8) 28/45 (62.2)
 Platelet count  8/25 (32.0)  5/19 (26.3)
  (< 150 × 109/L)
 Platelet count  4/25 (16.0)  3/19 (15.8)
  (> 450 × 109/L)
Biochemistry exams
 CRP (> 0.8 mg/dL)  18/19 (94.7) 13/15 (86.7)
 AST (> 40 IU/L)  5/16 (31.3) 1/15 (6.7)
 ALT (> 40 IU/L)  3/12 (25.0)  1/10 (10.0)
 BUN (> 20 mg/dL) 32/44 (72.7) 30/42 (71.4)
 Cr (> 1.2 mg/dL) 24/44 (54.5) 18/42 (42.9)
aData presented as number of positive cases/total cases (%). ALT = 
Alanine transaminase; AST = aspartate transaminase; BUN = blood 
urea nitrogen; Cr = creatinine; CRP = C-reactive protein; WBC = white 
blood cell count.
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Table 3. Univariate analysis in patients who received aerosolized colistin therapy for ventilator-associated pneumonia due to 
multidrug-resistant Acinetobacter baumannii (n = 45)a
Variable Surviving (n = 26)  Casualty (n = 19) χ2/t p
Patient characteristic
 Age (yr) 68.4 ± 16.6 74.0 ± 12.6 –1.225 0.227c
 Sex   0.116 0.734b
  Male 19 (73.1) 13 (68.4)
  Female 7 (26.9) 6 (31.6)
Comorbidity
 Pulmonary disease    0.046d,*
  No 16 (61.5) 17 (89.5)
  Yes 10 (38.5) 2 (10.5)
 Hypertension   0.137 0.712b
  No 15 (57.7) 12 (63.2)
  Yes 11 (42.3) 7 (36.8)
 Cardiovascular disease   0.003 0.954b
  No 18 (69.2) 13 (68.4)
  Yes 8 (30.8) 6 (31.6)
 Hepatic disease    0.565c
  No 25 (96.2) 17 (89.5)
  Yes 1 (3.8) 2 (10.5)
 Diabetes mellitus   0.319 0.572b
  No 21 (80.8) 14 (73.7)
  Yes 5 (19.2) 5 (26.3)
 Renal disease   0.616 0.433b
  No 18 (69.2) 11 (57.9)
  Yes 8 (30.8) 8 (42.1)
 Neurologic disease    0.517d
  No 18 (69.2) 15 (78.9)
  Yes 8 (30.8) 4 (21.1)
 Neoplastic disease    0.433d
  No 23 (88.5) 15 (78.9)
  Yes 3 (11.5) 4 (21.1)
 Operation    0.377d
  No 24 (92.3) 15 (78.9)
  Yes 2 (7.7) 4 (21.1)
APACHE II on ICU admission 22.5 ± 7.1 22.6 ± 6.3 –0.058 0.954c
APACHE II on 1st day of aerosolized 17.0 ± 5.5 21.5 ± 5.2 –2.798 0.008c*
 colistin administration
Length of stay (d)
 In hospital 73.9 ± 34.6 53.3 ± 30.5 2.064 0.045c*
 In ICU 30.0 ± 11.8 38.9 ± 20.4 –1.841 0.072c
Laboratory reportse 
 WBC (× 109/L) 11.69 ± 3.82 14.39 ± 7.87 –1.385 0.179c
 Segment WBC (%)  75.6 ± 8.6 79.9 ± 11.0 –1.469 0.149c
 Platelet (× 109/L) 356.5 ± 209.3 159.6 ± 120.3 2.379 0.029c*
(Contd)
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agents, including carbapenems were frequently identified 
as the pathogens responsible for VAP.9,10 Colistin emerged 
as a promising therapeutic alternative.
Colistin (polymyxin E) was first produced by the 
growth of Bacillus polymyxa subsp. colistinus in1949,2 and it 
exerts bactericidal activity by binding to the bacterial cell 
membrane and disrupting its permeability, resulting in 
the leakage of intracellular components. In vitro colistin 
has a broad spectrum of action against Gram-negative 
aerobic bacilli, including some strains resistant to carbap-
enems, aminoglycosides, penicillins, cephalosporins and 
fluoroquinolones. However, Proteus mirabilis, Providencia 
spp., Serratia spp., Morganella morgannii, Burkholderia cepa-
cia and Stenotrophomonas maltophilia are naturally non-
susceptible to colistin.11,12–14 Severe adverse effects (i.e. 
nephrotoxicity and neurotoxicity) have been reported and 
led to the discontinuation of parenteral use of this drug 
in the 1970s and 1980s.
Most reports regarding the treatment of pneumonia 
with colistin involved parenteral administration. Levin 
et al15 reported their experiences with 60 patients who 
had nosocomial infections caused by MDR P. aeruginosa 
and MDR A. baumannii. Patients with pneumonia had a 
much less favorable outcome (25% compared with the 
overall outcome of 58%). The amount of data available re-
garding demographic and clinical characteristics of VAP 
due to Gram-negative bacilli susceptible to colistin only is 
quite limited.1,14,15 Rios et al14 studied 61 episodes of VAP 
caused by Acinetobacter spp. or P. aeruginosa, of which 31 
isolates were colistin-only susceptible micro-organisms. 
They demonstrated that previous VAP episodes and prior 
antimicrobial therapy for > 10 days are risk factors for 
contracting colistin-only susceptible VAP. They concluded 
that colistin-susceptible VAP episodes could be effectively 
treated by intravenous colistin without significant renal 
dysfunction.
The main adverse effect of colistin treatment is renal 
failure, especially in patients with abnormal creatinine lev-
els. Even though several published studies demonstrated 
that the efficacy and safety of colistin for the treatment of 
nosocomial infection caused by MDR Gram-negative bac-
teria,16–18 renal dysfunction was still frequently reported 
to be a major adverse effect.1,15,19 Michalopoulos et al2 and 
Markou et al19 reported the incidence of nephrotoxicity to 
be 18.6% and 14.3%, respectively in their ICU studies using 
9 × 106 units of colistimethate sodium per day. Falagas 
et al20 analyzed 19 prolonged intravenous colistin courses 
(mean dosage = 4.4 million IU/day; mean treatment dura-
tion = 43.4 days) in 17 patients, and found the median 
serum creatinine value increased by only 0.25 mg/dL dur-
ing the treatment period compared with the baseline level 
(p < 0.001). However, a review article by Falagas and 
Kasiakou21 suggests that the incidence of nephrotoxicity 
in recently published reports regarding the experiences 
with polymyxins is less common and less severe than 
suggested by the studies in the 1970s.
Many previous studies have shown that multiple fac-
tors (i.e. advanced age, severe sepsis, low cardiac output 
Table 3. (Continued)
Variable Surviving (n = 26)  Casualty (n = 19) χ2/t p
Laboratory reportse (Contd)
 CRP (mg/dL) 7.2 ± 7.4 9.1 ± 2.7 –0.502 0.624c
 AST (IU/L) 33.8 ± 14.6 31.3 ± 5.6 0.386 0.705c
 ALT ( IU/L) 25.5 ± 17.7 16.2 ± 8.8 1.121 0.295c
 BUN (mg/dL) 37.5 ± 32.8 66.9 ± 35.7 –2.727 0.009c*
 Cr (mg/dL) 1.4 ± 1.5 2.9 ± 2.0 –2.712 0.010c*
Follow-up culturesf    0.035d*
 Positive 12 (46.2) 15 (78.9)
 No follow-up data 14 (53.8) 4 (21.1)
aData represented mean ± standard deviation or n (%); bχ2 test; ct test of independent samples; dFisher’s exact test; eafter aerosolized colistin 
administration; ffollow-up cultures of bronchial secretion or bronchoalveolar lavage; *p < 0.05. APACHE II = Acute physiological and Chronic 
Health Evaluation; ALT = alanine transaminase; AST = aspartate transaminase; BUN = blood urea nitrogen; Cr = creatinine; CRP = C-reactive 
protein; ICU = intensive care unit; WBC = white blood cell count.
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syndrome and hypovolemia) are associated with acute 
renal failure in the critically ill patients in the ICU set-
ting.22 Therefore, aerosolized colistin could be a reasonable 
choice for minimizing systemic exposure and to optimize 
the benefit-risk ratio of therapy.
Administration of polymyxins via inhalation has been 
adopted and recommended as the adjunctive treatment 
for MDR pneumonia.23 Ratjen et al24 studied the pharma-
cokinetics of inhaled colistin in patients with CF. The low 
systemic and high local concentrations of colistin sup-
port the use of inhaled colistin in CF patients infected 
with P. aeruginosa. Although the above finding sounds 
promising, it is not known whether this information can 
be extrapolated to non-CF patients with MDR nosocomial 
pneumonia.
There have been many studies assessing the efficacy of 
aerosolized colistin or polymyxin B in combination with 
intravenous antibiotic treatment in critically ill patients 
with VAP caused by MDR Gram-negative pathogens.4,6,25–29 
Although the experience with aerosolized colistin therapy 
is limited, it is believed that this alternative treatment is 
associated with more favorable outcomes, which means 
this approach merits further evaluation.
The major finding of our study is that aerosolized col-
istin may be an effective and safe adjunctive treatment for 
VAP due to MDR A. baumannii (especially colistin-only sus-
ceptible isolates) for critically ill patients. Michalopoulos 
et al4 conducted a small retrospective study of eight pa-
tients with pneumonia due to A. baumannii or P. aeruginosa 
(in which half of the cases were caused by colistin-only 
susceptible pathogens). Aerosolized colistin was adminis-
tered in conjunction with systemic colistin or other effec-
tive antibiotics. The cure rate for pneumonia was 7/8 
(88%). Recently, a prospective study designed to assess the 
effectiveness of aerosolized colistin as adjunctive treat-
ment for VAP due to MDR Gram-negative bacteria, also 
demonstrated favorable microbiological and clinical 
responses in 50/60 patients (83.3%).6
Conversely, our study found only 57.8% of patients 
had clinically favorable outcomes and 37.8% had micro-
biologic eradication. Both results were not as promising 
as those in other published reports.4–6 The difference in 
outcomes may be related to differences in patient charac-
teristics, potencies of commercial formulations of colistin 
in different countries, or to other causes. In our study, we 
prescribed aerosolized colistin with concomitant intrave-
nous antibiotics (colistin or other antimicrobial agents) 
for treating MDR A. baumannii VAP. Both persistent growth 
of the responsible pathogen (29.6% in positive cultures) 
and other colistin-resistant species (S. maltophilia, Chryseo-
bacterium sp., and M. morganii) were identified. Because 
these colistin-resistant isolates remained susceptible to 
other antibiotics, the subsequent results of microbiologic 
examinations become very important for evaluating the 
efficacy of the therapy. The data showed either resistance 
to colistin or development of concomitant infection with 
colistin-resistant pathogens. Unfortunately, a high pro-
portion of patients (18/45 patients) had no subsequent 
culture data after aerosolized colistin administration in 
our retrospective study.
This study showed several significant influential fac-
tors related with death by univariate analysis (Table 3). The 
clinicians in our hospital prescribed inhaled colistin for 
patients with MDR A. baumannii VAP because of deterio-
rating renal function in those patients. It is interesting that 
logistic regression analysis showed that the mortality OR 
for creatinine (after receiving aerosolized colistin therapy) 
was higher (OR = 7.558) even though there was significant 
difference (p = 0.115). Thus impairment of renal function 
should not be attributed solely to colistin toxicity, as other 
factors such as the development of septic shock, multi-
organ failure, and the use of other nephrotoxic agents in 
the ICU may also contribute to this condition. As a result, 
we strongly recommend monitoring renal function during 
colistin administration (both aerosolized and intravenous).
Treatment with aerosolized colistin may also be com-
plicated by bronchospasm, although this could be elimi-
nated by aerosolized β2-agonists used before the initiation 
of inhaled colistin.9 As in other published reports,4–6 there 
were no adverse effects related to aerosolized colistin seen 
in our study. Colistin heteroresistance had been reported 
among colistin-susceptible Acinetobacter isolates.30 In one 
study that aimed to assess potential risk factors for the 
isolation of colistin-resistant A. baumannii, Klebsiella pneu-
monia, and P. aeruginosa in hospitalized patients, the use of 
colistin was identified as the only independent risk factor 
(adjusted OR = 7.78; p < 0.001).31 Thus polymyxins should 
be used both rationally and carefully to decrease the rate of 
emergence of pan drug-resistant (resistant to all available 
antibiotics, including colistin) infections.
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Though this is the first study of aerosolized colistin 
treatment in Taiwan, this study has several limitations. 
It is a retrospective study on a relatively reduced number 
of patients and we did not have a control group contain-
ing patients with MDR A. baumannii VAP that received 
only intravenous antimicrobial agents. Furthermore, some 
of the patients also received intravenous colistin (n = 6), 
which might have influenced the outcome. A randomized 
controlled study with a larger patient population is neces-
sary to establish the efficacy and safety of aerosolized col-
istin as an adjunct to intravenous treatment of MDR 
A. baumannii VAP in critically ill patients.
In conclusion, the data in this study suggest that 
aerosolized colistin may be considered as an adjunct to 
intravenous treatment in patients with VAP due to colistin-
susceptible MDR A. baumannii. In spite of some encourag-
ing findings, subsequent randomized controlled studies 
are still urgently needed. It is crucial to monitor sub-
sequent cultures from bronchial secretions or bronchial 
lavage in order to accurately evaluate the efficacy of the 
treatment and to identify possible concomitant infections 
by colistin-resistant pathogens.
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